Recent News
Read ArticleDr. Jack Cush reviews the news, journal articles and regulatory decisions from the past week. July is Gout: More than Flares month.
New research shows synovial lining enriched in macrophages expressing SPP1 (encoding osteopontin) in proximity to fibroblasts and fibrin deposits. SPP1+ macrophages degrade fibrin & promote fibroblast proliferation that deposit collagen & does the damage, joint remodeling. A new https://t.co/yFxwAYFPPb
Dr. John Cush @RheumNow ( View Tweet)
"People wish their enemies dead—but I do not; I say give them the gout, give them the stone!" — Mary Wortley Montagu
Dr. John Cush @RheumNow ( View Tweet)
Uric Acid: Is Lower Better?
There is good evidence that a serum urate less than 6 mg/dL is required to meaningfully reduce urate crystal and gout flare burden, but is even lower better and are there any tradeoffs?
https://t.co/W5FsDC5FG0 https://t.co/7mRgkg00uV
Dr. John Cush @RheumNow ( View Tweet)
Updated Algorithm for the Management of Restless Legs Syndrome
Diagnose: chronic vs intermittent RLS (no need for polysomnography)
Test Iron levels (& Rx if)
Consider: remove exacerbators; walking/massage/heat; carbidopa/ levodopa; pramipexole or ropinirole; low potency opioids; https://t.co/XdzIipw1X8
Dr. John Cush @RheumNow ( View Tweet)
Learn more about the fundamentals of CAR T-cell therapy and its investigational use in autoimmune disease.
Sponsored by Bristol Myers Squibb. https://t.co/VvTOYY3tvz
#CARTCellTherapy https://t.co/kaTom2dEnZ
Dr. John Cush @RheumNow ( View Tweet)
True or False: EULAR recommends glucocorticoids alone, without additional agents, for remission induction in life-threatening ANCA-associated vasculitis.
Did you get it right? Take this week's RheumIQ quiz at https://t.co/TBlB4pmnKa. https://t.co/4IsId6lJ4Y
Dr. John Cush @RheumNow ( View Tweet)
In a claims analysis, 28.1% of patients with PsA had ≥1 predictor of IBD development at PsA diagnosis. 📊Which predictors had the highest association with future IBD? Click to learn more: https://t.co/x2pM0T9LWg
Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/uDxtvPAgOK
Dr. John Cush @RheumNow ( View Tweet)
True or False: There is an available antidote for colchicine overdose. Check your answer in this week's RheumIQ at https://t.co/TBlB4pmnKa. https://t.co/RgJ4xEAuZA
Dr. John Cush @RheumNow ( View Tweet)
The mortality gap in gout has not improved in 20 years – CV disease is the leading cause of death (2-fold increase).
For more gout content, follow our Gout: More than Flares campaign at https://t.co/xnBVBN5IXZ, https://t.co/c12GmMaatt
Dr. John Cush @RheumNow ( View Tweet)
TNR: Gout Journal Club
https://t.co/vWNEof3F6b https://t.co/EgfqfKU1lx
Dr. John Cush @RheumNow ( View Tweet)
Saliva and Uric Acid Testing
A recent report from China reaffirms the potential utility of salivary uric acid (UA) testing delivers smartphone-guided, enzyme-free gout screening at home for pennies per test.
Read Article
QD Clinic: Cellulitis Paradoxes
Dr. Richard Conway, Dublin, discusses a case of cellulitis and gout. Presented as part of RheumNow's "Gout: More than Flares" campaign during the month of July 2026.
https://t.co/ZeYyISJrrE https://t.co/2Ih4QRa7FK
Dr. John Cush @RheumNow ( View Tweet)
FDA Delays Gout Drug NASP with Complete Response Letter
On June 26, 2026, SOBI received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) that will delay a decision on NASP, pending the company's answer to questions regarding the drugs https://t.co/NmPbWmYd0p
Dr. John Cush @RheumNow ( View Tweet)
Non-gout drugs that may lower uric acid – losartan, amlodipine, ACE inhibitors, fenofibrate, atorvastatin, leflunomide, vitamin C, estrogen, and high-dose ASA.
For more gout content, follow our Gout: More than Flares campaign at https://t.co/xnBVBN5IXZ, https://t.co/vmNvqojAcS
Dr. John Cush @RheumNow ( View Tweet)
Problems with treatment adherence in the management of gout
Compared to common medical conditions such as hypertension, type 2 diabetes, hyperlipidemia or osteoporosis, where the reported drug adherence rates are between 50% to 70%, the drug adherence for gout is 37%. This https://t.co/OoLh0HUUH2
Dr. John Cush @RheumNow ( View Tweet)
🎥 In this RheumNow Therapeutic Update, Dr. Nicola Dalbeth reviews the latest evidence on the Outcomes of Tophaceous Gout and what every rheumatologist should know.
Watch now: https://t.co/KQmkdziLF5
#Gout #Rheumatology #MedEd #SystemicBurdenOfGout https://t.co/h8LhE5XW00
Dr. John Cush @RheumNow ( View Tweet)
Netherlands pragmatic open-label RCT from 8 rheum centres tested T2T vs Sx Rx in 308 Gout pts starting ULT (87% male; 66 yrs). Remission (no flares & pain < 2) betw 18-24 mos was more in T2T pts (39% vs 24%; p=0.02), but more AE w/ Sx driven Rx (53 vs 42%) https://t.co/5g2dY5y900
Dr. John Cush @RheumNow ( View Tweet)
Raynauds: Using the Clinical Practice Research Datalink Aurum (PCP) database (1998 - 2023) the prevalence of Raynaud’s 894/100 000, or 158449 cases in 2023. More in elderly & females, less in blacks. Incidence rate 46/100K https://t.co/S5Eg4AZSPU https://t.co/nG2p2g2Jc1
Dr. John Cush @RheumNow ( View Tweet)
Challenges in Gout Diagnosis
Dr. Angelo Gaffo in Birmingham, AL discusses the challenges in diagnosing gout. Presented as part of RheumNow's "Gout: More than Flares" campaign during the month of July 2026.
https://t.co/LmTj7cvBGT https://t.co/VRVCrAo2TT
Dr. John Cush @RheumNow ( View Tweet)
Video
From the Blog
At first, it seemed similar to many other such sessions – a circle of folding chairs, a group of colleagues whose visages exuded understanding and acceptance – but this was special. I started the meeting…. “Hi, my name is Artie.”
Read Post
Podcasts
Gout Cavalcade (7.10.2026)
Gout Journal Club
Podcast Replay: Is it Time to Transition MOAs in RA?
ICYMI: Great Lectures; Great Presentations
Therapeutic Updates
Fundamentals of CAR T Cell Therapy and Its Investigational Use in Autoimmune Diseases
Sponsored By Bristol Myers Squibb
Learn more about the fundamentals of CAR T-cell therapy and its investigational use in autoimmune disease
Read Post
Watch our 'Systemic Burden of Gout' series as part of this month's Gout More than Flares campaign. Now available: 3 New Things It Pays to Know About Gout Pathobiology, Outcomes of Tophaceous Gout & Subclinical Inflammation in Intercritical Gout.
Read Post
Poster Hall
Daily Gem
Gout patients are at greater risk for dementia, sleep apnea, septic arthritis and erectile dysfunction.
--